Shree Ganesh Remedies Ltd.

As of June 30, 2026, Shree Ganesh Remedies Ltd. carries a market capitalization of 8.20B, placing it among publicly traded companies globally. Its enterprise value stands at 8.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shree Ganesh Remedies Ltd. has 12.84M shares outstanding.

As of June 30, 2026, Shree Ganesh Remedies Ltd. trades at a trailing price-to-earnings ratio of 53.16.

As of June 30, 2026, Shree Ganesh Remedies Ltd. trades at an EV/EBITDA multiple of 26.39 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 39.85 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 8.20B versus a market cap of 8.20B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 5.31M in revenue per employee across its workforce of 186.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Shree Ganesh Remedies Ltd. recorded 55.09M in income tax expense. That works out to an effective tax rate of 26.30, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 209.48M, leaving 154.39M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Shree Ganesh Remedies Ltd.'s stock has gained approximately 27.12% over the past 52 weeks. The 50-day moving average sits at 640.28, while the 200-day moving average is 567.76.

Over the twelve months ended June 30, 2026, Shree Ganesh Remedies Ltd. generated 989.78M in revenue and converted that into 154.39M in net income, yielding earnings per share of 12.02. EBITDA reached 310.72M, while operating income came in at 205.78M.

Over the twelve months ended June 30, 2026, Shree Ganesh Remedies Ltd. posted a gross margin of 64.40, reflecting its pricing power and cost economics. The operating margin of 20.79 and net profit margin of 15.60 provide insight into operational efficiency.

Shree Ganesh Remedies Ltd.'s most recent stock split took place on February 3, 2023 with a 140:141 split ratio.